Skip to content

21-036 - AALL1631 - Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Status: open

AALL1631 - International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Treatment for Pediatric Oncology - lymphoblastic leukemia

Contact Us


To compare disease free survival (DFS) of Standard Risk (SR) pediatric Ph+ ALL treated with continuous imatinib combined with either a high-risk COG ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.


This trial is sponsored by Children's Oncology Group.

Providers Associated With This Trial

Principle Investigator

This link will open in a new tab or window.